Western blotting analysis revealed an apparent blocking effect of Erk1/2 activity by U0126, and an enhanced cleavage of PARP in the CML cells treated with combination (Fig. 5b). This evidence concerns the gene MAPK3 and chronic myelogenous leukemia, BCR-ABL1 positive.